{"url":"https://newsforagent.com/news/2026-10-26/recursion-rec-4881-fap-webinar","markdown_url":"https://newsforagent.com/news/2026-10-26/recursion-rec-4881-fap-webinar.md","title":"Recursion Sets Nov. 3 Webinar on REC-4881 FAP Data","headline":"Recursion to Report Q3 2026 Results Nov. 2 and Host Nov. 3 Webinar on Updated REC-4881 FAP Data","description":"Recursion will report third quarter 2026 results on November 2 and present updated REC-4881 data from the CGA-IGC Annual Meeting on November 3.","section":"Business","published_at":"2026-10-26T20:39:23+00:00","modified_at":"2026-10-26T20:39:23+00:00","author":"News Desk","key_takeaways":["Recursion will release third quarter 2026 financial results on November 2, 2026, after the close of US markets.","The November 3, 2026 webinar will present updated REC-4881 data from the CGA-IGC Annual Meeting in Denver, Colorado.","Recursion expects a regulatory update for REC-4881 by the end of the year."],"companies":[{"name":"Recursion Pharmaceuticals","is_primary":true,"profile_url":"https://akta.pro/company-profiles/00007ed/recursion-pharmaceuticals","website":"https://www.recursion.com"}],"source":{"publisher":"GlobeNewswire","title":"Recursion to Host Webinar Focused on Updated REC-4881 (FAP) Data from CGA-IGC on Tuesday, November 3","url":"https://www.globenewswire.com/news-release/2026/10/26/3388539/0/en/recursion-to-host-webinar-focused-on-updated-rec-4881-fap-data-from-cga-igc-on-tuesday-november-3.html"},"other_sources":[],"tags":["Business","Recursion Pharmaceuticals"],"body_markdown":"[Recursion](https://akta.pro/company-profiles/00007ed/recursion-pharmaceuticals) will report its third quarter 2026 financial results on November 2, 2026, after the close of US markets, and host a webinar on November 3, 2026, presenting updated REC-4881 data from the CGA-IGC Annual Meeting in Denver, Colorado, [GlobeNewswire](https://www.globenewswire.com/news-release/2026/10/26/3388539/0/en/recursion-to-host-webinar-focused-on-updated-rec-4881-fap-data-from-cga-igc-on-tuesday-november-3.html) reported. The webinar begins at 8:00 am ET, 6:00 am MT and 1:00 pm GMT.\n\n## Recursion's November 3 Webinar Agenda\n\nThe call will feature a third quarter recap from Najat Khan, Ph.D., Chief Executive Officer and President of Recursion, including encouraging REC-1245 monotherapy data, as well as a presentation of REC-4481 data from the company's CGA-IGC plenary presidential presentation. Vicki Goodman, M.D., Chief Medical Officer of Recursion, will moderate a KOL panel providing contextualization of the data, including a natural history perspective and relevance to unmet need in FAP, from global FAP specialists Bryson Katona, M.D., Ph.D., Director of the GI Cancer Genetics Program at the University of Pennsylvania Perelman School of Medicine and a TUPELO study investigator, and Evelien Dekker, M.D., Ph.D., Head of the Expert Clinic for Familial and Hereditary Polyposis and Colorectal Cancer and Principal Investigator of the Natural History Registry study at Amsterdam University Medical Center. A discussion moderated by Goodman will feature patient advocates sharing their experiences of living with FAP, a disease for which there are currently no approved pharmacotherapies. The company will broadcast the call from Recursion's X, LinkedIn and YouTube accounts, and investors, analysts and the public can submit questions to the company.\n\n## Recursion's REC-4881 Data and Financial Position\n\nRecursion is a clinical-stage TechBio company that uses AI and more than 50 petabytes of proprietary biological data to industrialize drug discovery, according to akta.pro [company records](https://akta.pro/company-data). The same records show FY 2025 revenue of $74.7 million, a 26.9% year-over-year increase from $58.8 million, and a FY 2025 net loss of approximately $644.8 million, compared with $463.7 million in 2024. Recursion held $665.2 million in cash as of Q1 2026, providing runway into early 2028.\n\n## REC-4881's Path to the November Webinar\n\nOn October 15, 2026, Recursion released updated REC-4881 data from its TUPELO study, showing 87% of FAP patients reduced polyp burden, with 92% among upper GI patients, Seeking Alpha reported. The same day, TradingView reported that Recursion announced a $200 million underwritten follow-on offering and updated clinical data for REC-4881 and REC-1245, with REC-4881 showing 47% median polyp burden reduction in FAP and REC-1245 a 91.7% disease control rate. On October 3, 2026, Simply Wall St reported that Recursion disclosed a two-year, non-exclusive RNA model license with Tempus AI for $12 million, plus access to de-identified pathology records.\n\n## What Comes After the Webinar\n\nRecursion expects a regulatory update for REC-4881 by the end of the year, ahead of the November 3 webinar.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}